Compare · CING vs NVO
CING vs NVO
Side-by-side comparison of Cingulate Inc. (CING) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CING and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 2524.2x CING ($85.4M).
- Over the past year, CING is up 35.7% and NVO is down 12.1% - CING leads by 47.8 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 4 for CING).
- NVO has more recent analyst coverage (25 ratings vs 4 for CING).
- Company
- Cingulate Inc.
- Novo Nordisk A/S
- Price
- $5.83+3.18%
- $48.65+3.65%
- Market cap
- $85.4M
- $215.46B
- 1M return
- +29.38%
- -2.08%
- 1Y return
- +35.70%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 9
- Recent ratings
- 4
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CING
- SEC Form 10-Q filed by Cingulate Inc.
- Cingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
- Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
- Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
- Cingulate Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4 filed by Chief Executive Officer Schaffer Shane J.
- SEC Form 4 filed by EVP & Chief Commercial Officer Downey Bryan Wade
- SEC Form 4 filed by Director Lawrence Bryan Jay
- SEC Form 4 filed by EVP and Chief Medical Officer Brams Matthew
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S